NO20064755L - Kombinasjonsterapi - Google Patents
KombinasjonsterapiInfo
- Publication number
- NO20064755L NO20064755L NO20064755A NO20064755A NO20064755L NO 20064755 L NO20064755 L NO 20064755L NO 20064755 A NO20064755 A NO 20064755A NO 20064755 A NO20064755 A NO 20064755A NO 20064755 L NO20064755 L NO 20064755L
- Authority
- NO
- Norway
- Prior art keywords
- cpt
- azd2171
- human
- antiangiogenic
- warm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår en metode for fremkalling av en antiangiogen og/eller kar-permeabilitet-reduserende effekt hos et varmblodig dyr, så som et menneske, som eventuelt behandles med ioniserende stråling, spesielt en metode for behandling av kreft, spesielt kreft som omfatter en fast tumor, som omfatter administrering av AZD2171 i kombinasjon med 5-FU, CPT-11 eller 5-FU og CPT-11; et farmasøytisk preparat som omfatter AZD2171 og 5-FU, CPT-11 eller 5-FU og CPT-11; et kombinasjonsprodukt som omfatter AZD2171 og 5-FU, CPT-11 eller 5-FU og CPT-11, for anvendelse i en metode for terapeutisk behandling av en menneske- eller dyrekropp; et sett som omfatter AZD2171 og 5-FU, CPT-11 eller 5-FU og CPT11; anvendelsen av AZD2171 og 5-FU, CPT-11 eller 5-FU og CPT-11 ved fremstilling av et medikament for anvendelse ved fremkalling av en antiangiogen og/eller karpermeabilitet-reduserende effekt hos et varmblodig dyr, så som et menneske, som eventuelt behandles med ioniserende stråling.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0406446.5A GB0406446D0 (en) | 2004-03-23 | 2004-03-23 | Combination therapy |
PCT/GB2005/001080 WO2005092303A2 (en) | 2004-03-23 | 2005-03-22 | Combination therapy with azd2171 and 5-fu and/or cpt-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064755L true NO20064755L (no) | 2006-10-20 |
Family
ID=32188482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064755A NO20064755L (no) | 2004-03-23 | 2006-10-20 | Kombinasjonsterapi |
Country Status (19)
Country | Link |
---|---|
US (1) | US20080125447A1 (no) |
EP (1) | EP1729808B1 (no) |
JP (1) | JP2007530518A (no) |
KR (1) | KR20060130763A (no) |
CN (1) | CN1964742A (no) |
AT (1) | ATE447974T1 (no) |
AU (1) | AU2005225193B2 (no) |
BR (1) | BRPI0508982A (no) |
CA (1) | CA2610628A1 (no) |
DE (1) | DE602005017591D1 (no) |
ES (1) | ES2335292T3 (no) |
GB (1) | GB0406446D0 (no) |
HK (1) | HK1096023A1 (no) |
IL (1) | IL177952A0 (no) |
MX (1) | MXPA06010758A (no) |
NO (1) | NO20064755L (no) |
NZ (1) | NZ549553A (no) |
WO (1) | WO2005092303A2 (no) |
ZA (1) | ZA200607555B (no) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0330002D0 (en) | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
AU2005225192B2 (en) * | 2004-03-23 | 2008-10-09 | Astrazeneca Ab | Combination therapy |
GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
NZ564189A (en) * | 2005-07-06 | 2011-04-29 | Astrazeneca Ab | Combination therapy of cancer with AZD2171 and gemcitabine |
NZ568812A (en) * | 2005-12-22 | 2011-09-30 | Astrazeneca Ab | Combination of AZD2171 and pemetrexed |
WO2015082880A1 (en) * | 2013-12-02 | 2015-06-11 | Astrazeneca Ab | Methods of selecting treatment regimens |
WO2020061391A1 (en) * | 2018-09-20 | 2020-03-26 | The Trustees Of Columbia University In The City Of New York | Methods for inhibiting tumor cells using inhibitors of foxo3a antagonists |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
KR20080015482A (ko) * | 1999-02-10 | 2008-02-19 | 아스트라제네카 아베 | 혈관형성 억제제로서의 퀴나졸린 유도체 |
US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
PL414997A1 (pl) * | 2001-02-19 | 2016-02-29 | Novartis Ag | Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do leczenia guzów litych nerki |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
AU2005288736B2 (en) * | 2004-09-27 | 2008-08-14 | Astrazeneca Ab | Cancer combination therapy comprising AZD2171 and imatinib |
NZ564189A (en) * | 2005-07-06 | 2011-04-29 | Astrazeneca Ab | Combination therapy of cancer with AZD2171 and gemcitabine |
WO2007068895A1 (en) * | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
NZ568812A (en) * | 2005-12-22 | 2011-09-30 | Astrazeneca Ab | Combination of AZD2171 and pemetrexed |
-
2004
- 2004-03-23 GB GBGB0406446.5A patent/GB0406446D0/en not_active Ceased
-
2005
- 2005-03-22 US US10/594,233 patent/US20080125447A1/en not_active Abandoned
- 2005-03-22 AU AU2005225193A patent/AU2005225193B2/en not_active Ceased
- 2005-03-22 NZ NZ549553A patent/NZ549553A/en unknown
- 2005-03-22 BR BRPI0508982-4A patent/BRPI0508982A/pt not_active IP Right Cessation
- 2005-03-22 ES ES05729381T patent/ES2335292T3/es active Active
- 2005-03-22 MX MXPA06010758A patent/MXPA06010758A/es active IP Right Grant
- 2005-03-22 AT AT05729381T patent/ATE447974T1/de not_active IP Right Cessation
- 2005-03-22 WO PCT/GB2005/001080 patent/WO2005092303A2/en active Application Filing
- 2005-03-22 EP EP05729381A patent/EP1729808B1/en active Active
- 2005-03-22 CN CNA2005800092182A patent/CN1964742A/zh active Pending
- 2005-03-22 CA CA002610628A patent/CA2610628A1/en not_active Abandoned
- 2005-03-22 DE DE602005017591T patent/DE602005017591D1/de active Active
- 2005-03-22 JP JP2007504467A patent/JP2007530518A/ja active Pending
- 2005-03-22 KR KR1020067021774A patent/KR20060130763A/ko not_active Application Discontinuation
-
2006
- 2006-09-07 IL IL177952A patent/IL177952A0/en unknown
- 2006-09-08 ZA ZA200607555A patent/ZA200607555B/en unknown
- 2006-10-20 NO NO20064755A patent/NO20064755L/no not_active Application Discontinuation
-
2007
- 2007-03-20 HK HK07103005.0A patent/HK1096023A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2005092303A2 (en) | 2005-10-06 |
EP1729808B1 (en) | 2009-11-11 |
MXPA06010758A (es) | 2006-12-15 |
ES2335292T3 (es) | 2010-03-24 |
ZA200607555B (en) | 2008-05-28 |
AU2005225193A1 (en) | 2005-10-06 |
ATE447974T1 (de) | 2009-11-15 |
US20080125447A1 (en) | 2008-05-29 |
CN1964742A (zh) | 2007-05-16 |
DE602005017591D1 (de) | 2009-12-24 |
EP1729808A2 (en) | 2006-12-13 |
JP2007530518A (ja) | 2007-11-01 |
WO2005092303A3 (en) | 2006-11-02 |
GB0406446D0 (en) | 2004-04-28 |
NZ549553A (en) | 2009-12-24 |
KR20060130763A (ko) | 2006-12-19 |
AU2005225193B2 (en) | 2008-10-09 |
IL177952A0 (en) | 2007-07-04 |
CA2610628A1 (en) | 2005-10-06 |
BRPI0508982A (pt) | 2007-08-28 |
HK1096023A1 (en) | 2007-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
NO20064755L (no) | Kombinasjonsterapi | |
MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
NO20056171L (no) | Kombinasjonsterapi | |
WO2005092384A3 (en) | Combination therapy with azd2171 and a platinum anti-tumour agent | |
NO20064754L (no) | Kombinasjonsterapi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |